ADP-receptor antagonist for treatment of inflammatory disease

摘要

A method of treating cardiovascular complications of inflammatory disease in an individual with an established inflammatory disease and having symptoms of active inflammation comprises a step of treating the individual with a suitable amount of an ADP-receptor antagonist. The inflammatory disease includes a disease selected from the group consisting of rheumatoid arthritis and psoriatic arthritis. The ADP-receptor antagonist may be clopridogel (PLAVIX). The method of the invention has the effect of reducing the risk of a patient with active inflammation having an atherothrombotic event as a side-effect of inflammatory disease. The patients are treated with from 5 to 900mg of an ADP-antagonist daily, with an optional loading dose of an ADP-receptor antagonist of between 300 and 900mg.